A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.
Clinical trial NCT00034619 · COMPLETED
Trial details
- NCT number
- NCT00034619
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.